NP / PA
Webb, Robert
Webb, Robert was paid $599K by Medicaid between Jan 2018 and Dec 2018, across 34 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 28% of everything it billed.
33Billing provider infoWEBB, ROBERT
LAS VEGAS, NV 89148
LAS VEGAS, NV 89148
33aNPI1154412385assigned 09/26/2006
33bProvider typePhysician Assistant
28Total paid$599K
24GClaims11,871
24DCodes billed34
24AFirst – last monthJan 2018 – Dec 2018
Compared with peers
Next to other Physician Assistant providers in Nevada
Rank by total paid#6 of 191
Median peer was paid$9K
This provider vs. median69×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,871 | $599K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 28% | 4,085 | 1,847 | $167K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 22% | 885 | 381 | $129K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 1,777 | 1,618 | $102K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 13% | 595 | 552 | $77K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.8% | 1,079 | 1,016 | $47K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 5.0% | 305 | 298 | $30K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 2.6% | 286 | 286 | $15K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.8% | 173 | 172 | $11K |
| 93000 | <1% | 479 | 471 | $5K | |
| 93923 | <1% | 50 | 50 | $4K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 338 | 338 | $3K |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 127 | 127 | $2K |
22 more codes
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 129 | $1K |
| 94010 | <1% | 50 | $1K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 43 | $527.11 |
| 81002 | <1% | 226 | $438.19 | |
| 82948 | <1% | 157 | $426.29 | |
| 80061 | Lipid panel | <1% | 43 | $366.82 |
| 80053 | Comprehensive metabolic panel | <1% | 47 | $307.96 |
| 81025 | <1% | 59 | $306.87 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49 | $281.91 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 25 | $230.08 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 25 | $212.64 |
| 99406 | <1% | 17 | $97.70 | |
| 82043 | <1% | 13 | $55.45 | |
| 82947 | <1% | 21 | $13.40 | |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 158 | $0.00 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | 0% | 43 | $0.00 |
| 1111F | 0% | 12 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 28 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 107 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 202 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 189 | $0.00 |
| 99497 | 0% | 49 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.